NasdaqCM:AGENBiotechs
Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise
Agenus (AGEN) is back in focus after fresh Phase 1b data on its botensilimab plus balstilimab regimen in refractory microsatellite stable metastatic colorectal cancer, as well as an oversubscribed private placement tied to its planned ROBBIN Phase 3 trial.
See our latest analysis for Agenus.
Agenus has been highly volatile, with the share price return up 45.1% over the past week and 57.3% year to date, but the 1 year total shareholder return is still down 18.3% and the 5 year total...